Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02996240 · ClinicalTrials.gov registry record · NA
Breast, Omega 3 Free Fatty Acid, Ph 0
A NA study, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- NA
- Development phase
- 21
- Enrollment target
NCT02996240: Completed NA study, sponsored by The University of Texas Health Science Center at San Antonio.
NCT02996240 is a NA study that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 21 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02996240, a NA study, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
Study Summary
Assess the impact of dietary omega 3 free fatty acids breast cancer patients.
Interventions
- DIETARY_SUPPLEMENT Omega-3 FFA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2017-06-12 |
| Est. Completion | 2021-02-22 |
| Phase | NA |
What the finished NCT02996240 record still lists
NCT02996240 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Omega-3 FFA is the first listed.
NCT02996240 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02996240 about?
NCT02996240 is a clinical study titled "Breast, Omega 3 Free Fatty Acid, Ph 0". Assess the impact of dietary omega 3 free fatty acids breast cancer patients.
What is the current status of trial NCT02996240?
This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2017-06-12. Estimated completion is 2021-02-22.
What interventions are being tested in trial NCT02996240?
The interventions under investigation include: Omega-3 FFA (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02996240?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02996240's enrollment target sits among peer trials
21 1762nd of 2000 higher than 233 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI